Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.20.4
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
USD ($)
Oct. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2019
USD ($)
agreement
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaborations                      
Accounts receivable       $ 10,111,000         $ 15,973,000 $ 10,111,000  
Collaborative arrangement                      
Collaborations                      
Contingent payments                 607,200,000    
Specified Development Events | Collaborative arrangement                      
Collaborations                      
Contingent payments                 67,500,000    
Specified Regulatory Events | Collaborative arrangement                      
Collaborations                      
Contingent payments                 163,700,000    
Specified Product Launch Events | Collaborative arrangement                      
Collaborations                      
Contingent payments                 376,000,000.0    
Grifols                      
Collaborations                      
Nonrefundable upfront payment   $ 5,000,000.0                  
Upfront payment received   $ 30,000,000.0       $ 30,000,000.0          
Contingent payments                 277,500,000    
Revenue recognized               $ 20,000,000.0      
Revenue, cumulative catch-up               $ 25,000,000.0      
Grifols | Licensed Rights                      
Collaborations                      
Revenue recognized                 39,900,000    
Grifols | Research Services                      
Collaborations                      
Deferred revenue related to upfront payment                 1,600,000    
Revenue recognized                 3,800,000    
Grifols | One-time delivery of drug supply for commercialization                      
Collaborations                      
Revenue recognized                 651,000    
Grifols | Exercise of option to include additional territories                      
Collaborations                      
Revenue recognized                 500,000    
Grifols | Commercial Milestones                      
Collaborations                      
Contingent payments           297,500,000          
Kissei                      
Collaborations                      
Upfront payment received             $ 33,000,000.0        
Contingent payments             $ 147,000,000.0        
Revenue recognized                 0    
Revenue, remaining performance obligations                 33,000,000.0    
Daiichi | Collaborative arrangement                      
Collaborations                      
Revenue recognized                 2,100,000    
fostamatinib | Grifols                      
Collaborations                      
Collaborative payment received     $ 20,000,000.0                
Markup percentage       30.00%              
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                      
Collaborations                      
Upfront payment received           17,500,000          
Collaborative payment received     17,500,000                
fostamatinib | Grifols | Creditable advance royalty payment                      
Collaborations                      
Upfront payment received           $ 2,500,000          
Collaborative payment received     $ 2,500,000                
fostamatinib | Grifols | Maximum                      
Collaborations                      
Royalty payment as a percentage of net sales           30.00%          
fostamatinib | Kissei                      
Collaborations                      
Upfront payment received                     $ 33,000,000.0
Revenue recognized                   $ 1,600,000 $ 30,600,000
Revenue, remaining performance obligations                 $ 1,400,000    
fostamatinib | Medison Pharma | Financing arrangement                      
Collaborations                      
Upfront payment received         $ 5,000,000.0            
fostamatinib | Medison Pharma | Commercial and license agreements                      
Collaborations                      
Number of agreements | agreement         2            
Subsequent event                      
Collaborations                      
Upfront payment received $ 125,000,000.0